Access cutting-edge community-acquired pneumonia treatment through this clinical trial at a research site in Chicago. Study-provided care at no cost to qualified participants.
Access community-acquired pneumonia specialists in Chicago at no cost
This study follows strict safety protocols and ethical guidelines
All study-related community-acquired pneumonia treatment provided free
REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia. The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of patients admitted to intensive care with community-acquired pneumonia. In addition, REMAP-CAP provides and adaptive research platform for evaluation of multiple treatment modalities in the event of a respiratory pandemic such as COVID-19. REMAP-COVID is a sub-platform of REMAP-CAP th
Sponsor: UMC Utrecht
Check if you qualify for this community-acquired pneumonia clinical trial in Chicago, IL
If you're searching for community-acquired pneumonia treatment options in Chicago, IL, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Chicago research site is actively enrolling participants for this clinical trial. You'll receive care from experienced community-acquired pneumonia specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.